Stock Events

Stock Events

Viking Therapeutics 

€28.85
0
-€0.35-1.2% Today

Statistics

Day High
28.85
Day Low
28.75
52W High
40
52W Low
19.41
Volume
0
Avg. Volume
683
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29AprExpected
Q4 2025
Next
-1.16
-1.02
-0.89
-0.75
Expected EPS
-0.87718775324
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1VT.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.92B
Madrigal Pharmaceuticals focuses on the development of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, directly competing with Viking's work on metabolic disorders.
Viking Therapeutics
VKTX
Mkt Cap3.97B
Viking Therapeutics itself, as it's important to consider a company's position and pipeline in comparison to its own progress and future plans.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, positioning it as a competitor in the same therapeutic area as Viking.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.55M
Galmed Pharmaceuticals is developing therapies for liver diseases, including NASH, directly competing with Viking's liver disease focus.
Agios Pharmaceuticals
AGIO
Mkt Cap2.06B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, overlapping with Viking's interest in metabolic disorders.
Novartis
NVS
Mkt Cap297.35B
Novartis AG has a diverse portfolio that includes treatments for metabolic and liver diseases, making it a competitor in Viking's areas of interest.
Pfizer
PFE
Mkt Cap153.13B
Pfizer has a broad research portfolio that includes metabolic diseases and NASH, positioning it as a competitor to Viking Therapeutics.
AMGEN
AMGN
Mkt Cap189.22B
Amgen focuses on innovative human therapeutics, with a portfolio that includes treatments for cardiovascular and metabolic diseases, competing with Viking's therapeutic areas.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca has a diverse portfolio in various therapeutic areas, including metabolic diseases, making it a competitor to Viking Therapeutics.

About

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Brian Lian Ph.D.
Employees
45
Country
United States
ISIN
US92686J1060

Listings

MI
IT
1VKTX.MI
MU
DE
1VT.MU
STU
DE
1VT.STU
XNAS
US
VKTX

0 Comments

Share your thoughts

FAQ

What is Viking Therapeutics stock price today?▼
The current price of 1VT.STU is €28.85 EUR — it has decreased by -1.2% in the past 24 hours. Watch Viking Therapeutics stock price performance more closely on the chart.
What is Viking Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Viking Therapeutics stocks are traded under the ticker 1VT.STU.
Is Viking Therapeutics stock price growing?▼
1VT.STU stock has fallen by -4.76% compared to the previous week, the month change is a -7.5% fall, over the last year Viking Therapeutics has showed a +47.72% increase.
When is the next Viking Therapeutics earnings date?▼
Viking Therapeutics is going to release the next earnings report on April 29, 2026.
What were Viking Therapeutics earnings last quarter?▼
1VT.STU earnings for the last quarter are -1.16 EUR per share, whereas the estimation was -0.75 EUR resulting in a -55.01% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Viking Therapeutics have?▼
As of April 13, 2026, the company has 45 employees.
In which sector is Viking Therapeutics located?▼
Viking Therapeutics operates in the Health & Wellness sector.
When did Viking Therapeutics complete a stock split?▼
Viking Therapeutics has not had any recent stock splits.
Where is Viking Therapeutics headquartered?▼
Viking Therapeutics is headquartered in San Diego, United States.